Ipsen and GENFIT announce positive Phase 3 trial data
Ipsen and GENFIT announce positive topline data from the pivotal ELATIVE Phase III trial. In the trial the efficacy and safety of elafibranor, an investigational dual α,δ PPAR agonist, is
Fixed dose combination OCA/Bezafibrate positive interim Phase 2 study results.
Intercept Pharmaceuticals announces new data showing potential of Fixed-Dose Combination of OCA and Bezafibrate to normalize multiple biomarkers in PBC to be featured in podium presentation at EASL Congress June
Susan’s PBC Guest Blog
My name is Susan and I was diagnosed with PBC in 1992 at the age of 38. Information and support for PBC was difficult to find and disease outcomes available
PBC Guest Blog from Susan – June 5, 2023
My name is Susan and I was diagnosed with PBC in 1992 at the age of 38. There were no support groups at that time and the information on disease
In need of psychological support?
Join this 6 week research study for patients with Autoimmune Liver Disease. You will receive a self study manual, complete one chapter each week and receive weekly telephone support from
Linerixibat GLISTEN phase 3 study now enrolling
The GLISTEN clinical trial is investigating a potential new treatment specifically for PBC itch and is now enrolling patients worldwide. In Canada, the study is currently enrolling in Toronto, Ontario. Fixed-dose combination OCA/Bezafibrate granted orphan drug designation by FDA
Intercept Pharmaceuticals is investigating a fixed-dose combination of OCA and bezafibrate for the potential treatment of individuals with PBC. Clinical trials are underway to establish safety and efficacy. OCA, a
Sarka’s blog #10
I come from a line of very strong women. I am a strong woman. Living life to the fullest and surmounting what life can throw at you. Read more. Sarka’s PBC Blog #10 – April 5, 2023
Strong women I come from a line of very strong women. I am a strong woman. Loving. Powerful. Autonomous. Breaking barriers and going after dreams. Living life to the fullest